Literature DB >> 18352854

Augmentation therapy in alpha-1 antitrypsin deficiency.

Gustavo A Heresi1, James K Stoller.   

Abstract

BACKGROUND: Alpha-1 antitrypsin deficiency is a genetic disorder that leads to early-onset emphysema. Recently, exogenous supplementation of the enzyme has become a therapeutic alternative.
OBJECTIVE: To review the role of so-called augmentation therapy with pooled human plasma alpha-1 antitrypsin as a specific treatment for emphysema caused by alpha-1 antitrypsin deficiency.
METHODS: The authors performed a Medline (1966 - 2007) search with the keywords 'alpha-1 antitrypsin deficiency' and 'therapy'. The authors focused on articles regarding biochemical and clinical efficacy. RESULTS/
CONCLUSION: Augmentation therapy has been shown to raise antiprotease serum and epithelial lining fluid levels above the 'protective threshold' value. Evidence suggests that this approach slows the decline in lung function, could reduce infection rates, might enhance survival, and is well tolerated. Questions about the cost-effectiveness of this therapy remain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18352854     DOI: 10.1517/14712598.8.4.515

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  7 in total

Review 1.  Copd.

Authors:  Robert Andrew McIvor; Marcel Tunks; David Charles Todd
Journal:  BMJ Clin Evid       Date:  2011-06-06

2.  Hypersensitivity vasculitis with leukocytoclastic vasculitis associated with alpha-1-proteinase inhibitor.

Authors:  Nicola W Mwirigi; Charles F Thomas
Journal:  Case Rep Med       Date:  2010-02-24

Review 3.  Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.

Authors:  Peter C Gøtzsche; Helle Krogh Johansen
Journal:  Cochrane Database Syst Rev       Date:  2016-09-20

4.  Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Authors:  Mark L Brantly; Jeffrey D Chulay; Lili Wang; Christian Mueller; Margaret Humphries; L Terry Spencer; Farshid Rouhani; Thomas J Conlon; Roberto Calcedo; Michael R Betts; Carolyn Spencer; Barry J Byrne; James M Wilson; Terence R Flotte
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

Review 5.  Alpha1-antitrypsin deficiency: forgotten etiology.

Authors:  Alan Kaplan; Lidia Cosentino
Journal:  Can Fam Physician       Date:  2010-01       Impact factor: 3.275

6.  High-level expression of active human alpha1-antitrypsin in transgenic tobacco chloroplasts.

Authors:  M Nadai; J Bally; M Vitel; C Job; G Tissot; J Botterman; M Dubald
Journal:  Transgenic Res       Date:  2008-08-07       Impact factor: 2.788

Review 7.  Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis.

Authors:  R Siekmeier
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.